Clinical Trial Update: RNA Disruption Assay (RDA) Response Prediction in Neoadjuvant Chemotherapy Breast Cancer Treatment [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating RNA Disruption Assay as a predictor of response to neoadjuvant chemotherapy in invasive breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Invasive Breast Cancer

Snippet

Sponsor: Jewish General Hospital | Conditions: Invasive Breast Cancer | Phase 2 | Status: COMPLETED